Actis to infuse over $700 mn to develop life sciences assets

30 Jun 2022 CW Team

Actis is looking to expand its life sciences realty portfolio via its recent acquisition of Rx Propellant and is also looking at inorganic growth via a few more buyouts.

Partner and Head of India and SE Asia Real Estate at Actis, Ashish Singh, told the media that the life sciences sector of India holds huge potential for growth in the current decade, with a large talent pool at competitive cost making it a convincing destination for global research & development (R&D) and manufacturing.

The platform, which leases realty to research & development (R&D) labs and associated facilities of these firms will be developed to over 6 million sq ft from the current 1 million sq ft over the following five years. The company is looking to expand further in Mumbai, Hyderabad, and Bangalore where it already has an existence, and will also add properties in Ahmedabad and Pune.

The firm is planning to grow our operations in the life sciences sector via a buy and build program targeting both greenfield and brownfield assets with a focus on sustainability, Singh said.

He believes India is an evident beneficiary of the manufacturing and supply chains realignment as part of de-risking from China when it comes to the life sciences segment. Patents that currently account for the global market worth about $250 billion, are expiring between 2021 and 2026, and India is placed as a key beneficiary of this unlocking of the market.

India has been attracting a lot of global R&D work in the life sciences industry in the backdrop of an abundant high-quality talent pool and cost savings of around 65% to global corporations.

More outsourcing of this work is likely to push demand for the life sciences-related realty sector while no organised supply of real estate is available for these corporations in India presently as most of it stays fragmented.

Rx Propellant is looking to be a market-leading life science-focused realty developer-operator in India with its long-term partnerships in the Indian contract research organisations ecosystem.

Image Source

Also read: Actis acquires Rs 6,000 cr portfolio of six operating highway projects

A global investor in sustainable infrastructure, Actis is planning to infuse over $700 million to build and develop assets under its platform focused on providing real estate to tenants in the life sciences and related sectors in the country. Actis is looking to expand its life sciences realty portfolio via its recent acquisition of Rx Propellant and is also looking at inorganic growth via a few more buyouts. Partner and Head of India and SE Asia Real Estate at Actis, Ashish Singh, told the media that the life sciences sector of India holds huge potential for growth in the current decade, with a large talent pool at competitive cost making it a convincing destination for global research & development (R&D) and manufacturing. The platform, which leases realty to research & development (R&D) labs and associated facilities of these firms will be developed to over 6 million sq ft from the current 1 million sq ft over the following five years. The company is looking to expand further in Mumbai, Hyderabad, and Bangalore where it already has an existence, and will also add properties in Ahmedabad and Pune. The firm is planning to grow our operations in the life sciences sector via a buy and build program targeting both greenfield and brownfield assets with a focus on sustainability, Singh said. He believes India is an evident beneficiary of the manufacturing and supply chains realignment as part of de-risking from China when it comes to the life sciences segment. Patents that currently account for the global market worth about $250 billion, are expiring between 2021 and 2026, and India is placed as a key beneficiary of this unlocking of the market. India has been attracting a lot of global R&D work in the life sciences industry in the backdrop of an abundant high-quality talent pool and cost savings of around 65% to global corporations. More outsourcing of this work is likely to push demand for the life sciences-related realty sector while no organised supply of real estate is available for these corporations in India presently as most of it stays fragmented. Rx Propellant is looking to be a market-leading life science-focused realty developer-operator in India with its long-term partnerships in the Indian contract research organisations ecosystem. Image Source Also read: Actis acquires Rs 6,000 cr portfolio of six operating highway projects

Infrastructure Urban

09 Jan 2026

Mount Invests Rs 250 Cr, Adds PUF & PEB Plants, 400+ Jobs

TUMKUR, Karnataka, January 8, 2025 - Mount Roofing & Structures Private Limited, one of India's fastest-growing manufacturers in PUF and a leading solutions provider across Pre-Engineered Building (PEB) and Polycarbonate sheets, simultaneously inaugurated its second fully automated continuous Sandwich Panel manufacturing line and a new PEB manufacturing plant at its integrated campus in Tumkur." The milestone expansion, part of a total investment of INR 250 crores, marks a significant advancement in the company's commitment to engineered performance, manu..

Infrastructure Urban

09 Jan 2026

Titan Intech Strengthens UltraLED Push With Global LED Veteran

Titan Intech has announced the induction of global LED industry veteran Su Piow Ko to its Board of Directors, marking a strategic step in strengthening its UltraLED Displays roadmap and building globally competitive LED display solutions from India.The appointment aligns with Titan Intech’s ambition to position India as a hub for advanced, high-quality LED display manufacturing. With an increased focus on UltraLED Displays, the company aims to enhance technical governance, raise manufacturing standards and expand its presence across global markets.Su Piow Ko brings over three decades of inte..

Infrastructure Urban

09 Jan 2026

Dun & Bradstreet Flags New Growth Engines in India 2026 Outlook

Dun & Bradstreet has released its India 2026: D&B’s Perspective report, projecting a stable macroeconomic environment underpinned by fresh opportunities for productivity-led and inclusive growth. The report outlines how India’s next growth phase will be driven by digitised logistics, trusted data ecosystems, clean energy and rising city vitality.According to the outlook, India’s GDP growth is expected to reach around 6.6 per cent by FY2027, supported by resilient consumer demand and sustained public investment. Manufacturing is seen entering a new phase, moving beyond scale towar..